DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
Year: 2025
Type: article
Abstract: Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].
Source: Future Oncology
Institutions: Centre François Baclesse, Hospital Universitario Reina Sofía, Institut Curie, Agostino Gemelli University Polyclinic, Sungkyunkwan University, Saitama Medical University, National University of Singapore, National University Cancer Institute, Singapore, National University Hospital, Velindre Cancer Centre, Canberra Hospital, University of Brescia, Hôpital Civil, Strasbourg, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Caen Normandie
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4410091874